Send to

Choose Destination
Appl Transl Genom. 2013 May 26;2:3-16. eCollection 2013 Dec 1.

C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection.

Author information

Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.


When HIV was initially discovered as the causative agent of AIDS, many expected to find a vaccine within a few years. This has however proven to be elusive; it has been approximately 30 years since HIV was first discovered, and a suitable vaccine is still not in effect. In 2009, a paper published by Hutter et al. reported on a bone marrow transplant performed on an HIV positive individual using stem cells that were derived from a donor who was homozygous for a mutation in the CCR5 gene known as CCR5 delta-32 (Δ32) (Hütter et al., 2009). The HIV positive individual became HIV negative and remained free of viral detection after transplantation despite having halted anti-retroviral (ARV) treatment. This review will focus on CCR5 as a key component in HIV immunity and will discuss the role of CCR5 in the control of HIV infection.


CCR5; HIV; Therapeutics; Δ32

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center